This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,181,250 in funding to the Seattle Institute For Biomedical And Clinical Research to develop small molecule inhibitors of the MSUT2 protein as a potential therapeutic approach for treating tauopathy disorders such as frontotemporal lobar degeneration, Alzheimer's disease, and related conditions. The project aims to optimize potent and brain-penetrant MSUT2 inhibitors and demonstrate...
The University of Texas Medical Branch at Galveston will research immunotherapy targeting tau aggregate polymorphs under a $4.02 million project grant from the National Institute on Aging's Aging Research program (CFDA 93.866). The three-year award will support determining the efficacy of four monoclonal antibodies in targeting disease-relevant tau oligomeric strains/polymorphs implicated in neurodegenerative tauopathies like Alzheimer's disease and frontotemporal lobar degeneration. Researchers...
This Project Grant award, with a total funding amount of $431,750, was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The award is for the development and evaluation of a novel immuno-gene therapy approach using a single-chain fragment variable (scFv) derived from an anti-tau oligomeric complex 1 (TOC1) antibody. The key objectives are to: 1) generate and validate the TOC1-scFv-HaloTag-Proteasome Degradation Signal (PDS)...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $999,822 to Aeton Therapeutics Inc. to develop an anti-tau monoclonal antibody treatment for Alzheimer's disease. The key products and services to be delivered include: Evaluating the effectiveness of Aeton's lead candidate AT-01 in treating neural cells and organoids, compared to another anti-tau antibody HJ8.7, in in-vitro studies. Determining the efficacy and safety of AT-01 versus HJ8.7 in a...
This Project Grant award from the National Institute on Aging (NIA), under the Aging Research (CFDA 93.866) program, provides $2,836,419 to investigate how the SUT-6/NIPP1 protein regulates pathological tau in Alzheimer's disease and other tauopathies. The funded research aims to: Define the functions of SUT-6/NIPP1 important for suppressing tau toxicity by introducing mutations and evaluating effects in a C. elegans model of tau pathology. Determine downstream mediators of SUT-6/NIPP1's...
The University of Rochester received a $423,500 Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research program) to investigate the role of mitochondrial dysfunction and oxidative stress in the progression of tau pathology in Alzheimer's disease. The two-year project will utilize novel optogenetic tools to spatiotemporally control mitochondrial function and reactive oxygen species production in both ex vivo brain slice cultures and an in vivo mouse model of tau...
The University of Tennessee was awarded a $2,157,183 Project Grant from the National Institutes of Health National Institute on Aging to validate a novel tau clearance mechanism for the period of June 1, 2022 to May 31, 2025. The grant falls under the Aging Research program (CFDA 93.866), which supports biomedical, social and behavioral research on aging. The grant aims to elucidate the complex mechanisms underlying tauopathies such as Alzheimer's disease and develop effective therapeutic...
This Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), supports research at Case Western Reserve University investigating the role of RNA m6A modification in regulating tau protein metabolism and its impact on tauopathies, a group of neurodegenerative diseases. The $161,000 award, effective June 15, 2025 through May 31, 2027, aims to determine how depletion of the m6A methyltransferase METTL14 affects tau mRNA splicing and...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $773,816 to the University of California, Irvine to conduct a study on aberrant RNA splicing and misfolded protein accumulation in Alzheimer's-related tauopathies. The key products and services to be delivered include: Generating single-cell spatial proteo-transcriptomics maps to characterize aberrant RNA splicing and abnormal protein products in specific brain cell types exhibiting...
This Project Grant award from the National Institute on Aging (NIA), under the Aging Research (CFDA 93.866) program, will support research at Rutgers, The State University to investigate the role of mitochondrial deficits in tau protein pathology and autophagy defects associated with Alzheimer's disease (AD). The $431,750 award, effective June 1, 2025 through May 31, 2027, will enable the research team to determine the mechanisms by which the mitochondrial protein Miro enhances autophagy and tau...